Factive gemifloxacin mesylate: Phase III data

In a retrospective analysis of 4 Phase III trials in 1,969 patients, Factive was more effective than cefuroxime and trovafloxacin. In the 301 patients with allergic rhinitis, response rates were 89.3%...